ABZYME THERAPEUTICS LLC

Abzyme Therapeutics is a biopharmaceutical discovery and service company with expertise in modular antibody discovery and conditionally-active antibody engineering for immunotherapy using proprietary antibody generation and optimization platforms. Unique to Abzyme is a proprietary eukaryotic in vitro antibody discovery and optimization platform based on yeast-display, self-diversifying libraries, and rapid target-directed antibody affinity maturation combined with FACS single-cell sorting. The modular platform screens in real time for epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity, and target-specificity. The company has over 60 proprietary and partnered programs in therapeutic and diagnostic areas including infectious diseases, immuno-oncology, ophthalmology, inflammation, and central nervous system disorders, and is located in the Philadelphia biotechnology hub.